05.22.2023
Diagnostics
$4,616,101.00
36 months
A PrOspective RandoMIzed Study of Treatment Selection Based on Epigenetic Markers in CROHN's Disease: OMICROHN
A prospective controlled clinical validation trial to compare epigenome-based treatment with random treatment selection (current standard of care) in patients with active CD.